Header Logo

Connection

Angela Woodiwiss to Adrenergic beta-Agonists

This is a "connection" page, showing publications Angela Woodiwiss has written about Adrenergic beta-Agonists.
Connection Strength

2,881
  1. Limited Impact of ß-Adrenergic Receptor Activation on Left Ventricular Diastolic Function in Rat Models of Hypertensive Heart Disease. J Cardiovasc Pharmacol. 2018 11; 72(5):242-251.
    View in: PubMed
    Score: 0,623
  2. Prevention of ßeta-adrenergic-induced Adverse Cardiac Remodeling by Gonadectomy in Male but Not Female Spontaneously Hypertensive Rats. J Cardiovasc Pharmacol. 2017 Sep; 70(3):202-209.
    View in: PubMed
    Score: 0,575
  3. Reverse chamber remodelling following adrenergic-induced advanced cardiac dilatation and pump dysfunction. Basic Res Cardiol. 2012 Jan; 107(1):238.
    View in: PubMed
    Score: 0,387
  4. Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats. J Cardiovasc Pharmacol. 2010 Aug; 56(2):203-11.
    View in: PubMed
    Score: 0,352
  5. Impact of chronic beta-adrenoceptor activation on neurotensin-induced myocardial effects in rats. Eur J Pharmacol. 2006 Dec 28; 553(1-3):246-53.
    View in: PubMed
    Score: 0,269
  6. Impact of castration on changes in left ventricular diastolic pressure-volume relations induced by chronic adrenergic stimulation in rats. J Cardiovasc Pharmacol. 2014 Jun; 63(6):562-6.
    View in: PubMed
    Score: 0,115
  7. Telomere length and adrenergic-induced left ventricular dilatation and systolic chamber dysfunction in rats. Eur J Appl Physiol. 2013 Nov; 113(11):2803-11.
    View in: PubMed
    Score: 0,109
  8. Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats. Pflugers Arch. 2007 Nov; 455(2):251-60.
    View in: PubMed
    Score: 0,071
  9. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation. Am J Physiol Heart Circ Physiol. 2007 Apr; 292(4):H1898-905.
    View in: PubMed
    Score: 0,068
  10. Mechanisms of preserved baseline cardiac systolic function in rats with adrenergic inotropic downregulation. Life Sci. 2005 Dec 12; 78(4):366-75.
    View in: PubMed
    Score: 0,062
  11. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation. Hypertension. 2005 May; 45(5):914-20.
    View in: PubMed
    Score: 0,061
  12. A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension. S Afr Med J. 2004 Oct; 94(10):833-4.
    View in: PubMed
    Score: 0,059
  13. Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy. Hypertension. 2003 Mar; 41(3):499-504.
    View in: PubMed
    Score: 0,052
  14. Adenosine A2a-receptor activation enhances cardiomyocyte shortening via Ca2+-independent and -dependent mechanisms. Am J Physiol. 1999 05; 276(5):H1434-41.
    View in: PubMed
    Score: 0,040
  15. Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation. Pflugers Arch. 2006 May; 452(2):155-63.
    View in: PubMed
    Score: 0,016
  16. Antiadrenergic effects of adenosine in pressure overload hypertrophy. Hypertension. 2001 Mar; 37(3):862-8.
    View in: PubMed
    Score: 0,011
  17. Association analysis of beta2 adrenoceptor polymorphisms with hypertension in a Black African population. J Hypertens. 2000 Feb; 18(2):167-72.
    View in: PubMed
    Score: 0,011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.